Nonclinical Toxicology, Biodistribution, and Pharmacokinetics of UB-VV111, an <i>In Vivo</i> Anti-CD19 CAR T Cell TherapyAlissa Brandes, Ryan Larson, Travis J. Friesen et al.|Blood|2024Cited by 5
Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human PrimatesMaura H. Parker, Byoung Y. Ryu, Kristen Mittelsteadt et al.|Blood|2024Cited by 2